Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB-ATG Conditioning for HSCT in MDS and AML
NCT00915811Phase 2Terminated
- Sponsor
- King's College Hospital
- Start
- Jun 2007
- Primary completion
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, busulfan, antithymocyte globulin rabbit in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), sponsored by King's College Hospital. Started Jun 2007; status: terminated.
02
Drugs
fludarabinebusulfanantithymocyte globulin rabbit
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
Beyond the preview
Go deeper on NCT00915811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00915811.